Stephen D Mikolajczyk
Overview
Explore the profile of Stephen D Mikolajczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khan M, Sokoll L, Chan D, Mangold L, Mohr P, Mikolajczyk S, et al.
Urology
. 2004 Dec;
64(6):1160-4.
PMID: 15596190
Objectives: To investigate the clinical utility of the subforms of free prostate-specific antigen (PSA), namely proPSA and "benign" PSA (BPSA), to improve cancer detection when the percent free PSA level...
12.
Mikolajczyk S, Song Y, Wong J, Matson R, Rittenhouse H
Clin Biochem
. 2004 Jul;
37(7):519-28.
PMID: 15234233
Prostate specific antigen (PSA) is the most successful and widely employed cancer serum marker in use today. There is growing evidence that the introduction of wide PSA screening and earlier...
13.
Mikolajczyk S, Rittenhouse H
Rinsho Byori
. 2004 May;
52(3):223-30.
PMID: 15137320
Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer, but has limited specificity for distinguishing early prostate cancer(PCa) from benign disease since serum PSA can leak from...
14.
Canto E, Singh H, Shariat S, Lamb D, Mikolajczyk S, Linton H, et al.
Urology
. 2004 May;
63(5):905-10.
PMID: 15134977
Objectives: To determine whether the serum concentration of BPSA, a distinct form of free prostate-specific antigen (PSA) enriched in the nodular transition zone (TZ) tissue of benign prostatic hyperplasia (BPH),...
15.
Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Horninger W, et al.
J Urol
. 2004 May;
171(6 Pt 1):2239-44.
PMID: 15126794
Purpose: Pro forms of prostate specific antigen (PSA) have been reported to be more cancer specific markers of prostate cancer than total PSA and they also may preferentially detect the...
16.
Mikolajczyk S, Catalona W, Evans C, Linton H, Millar L, Marker K, et al.
Clin Chem
. 2004 Apr;
50(6):1017-25.
PMID: 15054080
Introduction: Pro or precursor forms of prostate-specific antigen (PSA) have emerged as potentially important diagnostic serum markers for prostate cancer detection. Immunoassays were developed to measure specific proPSA forms containing...
17.
Naya Y, Fritsche H, Bhadkamkar V, Mikolajczyk S, Rittenhouse H, Babaian R
Urology
. 2004 Mar;
63(3):492-8.
PMID: 15028444
Objectives: Recently, disease-specific isoforms of the prostate-specific antigen (PSA) have been identified. We evaluated the efficacy of precursor isoforms of PSA (pPSA) and an internally cleaved form of PSA referred...
18.
Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Amirkhan A, et al.
J Urol
. 2003 Nov;
170(6 Pt 1):2181-5.
PMID: 14634374
Purpose: Pro prostate specific antigen (pPSA) is a precursor form of PSA enriched in tumor compared to benign prostate tissues that may be a more specific serum marker for prostate...
19.
Khan M, Partin A, Rittenhouse H, Mikolajczyk S, Sokoll L, Chan D, et al.
J Urol
. 2003 Aug;
170(3):723-6.
PMID: 12913682
Purpose: In contemporary screening populations a major drawback of prostate specific antigen (PSA) is its relative lack of specificity, especially in the range of 4 to 10 ng/ml, where prostate...
20.
Mikolajczyk S, Rittenhouse H
Keio J Med
. 2003 Jul;
52(2):86-91.
PMID: 12862359
BPSA and proPSA are distinct molecular forms of free PSA in serum. BPSA is a form of free PSA that is associated with BPH. The inactive precursor of PSA, proPSA,...